丙型肝炎病毒感染与治疗药物

摘要

Hepatitis C virus (HCV) can lead to chronic hepatitis C (CHC) in ways that favor viral replication and persistent infection. The current standard treatment for hepatitis C virus infection is the combination ofpegylated IFN with ribavirin (PEG-IFN/RBV). In the recent years there has been significant advances in the understanding of viral replication and the development of anti-virus agents. This review summarizes the current knowledge of HCV cell entry, replication, escaping host innate and adaptive immune responses and current clinical trails of anti-HCV drugs.%丙型肝炎病毒(HCV)通过在宿主细胞内持续复制,导致慢性感染.目前用于治疗慢性丙型肝炎(CHC)的药物主要是聚乙二醇干扰素(PEG-IFN)和利巴韦林的联合用药.本文将就HCV的细胞入侵、复制、逃避宿主的固有和获得性免疫,以及抗HCV临床试验药物的最新进展做-综述.